{
    "nct_id": "NCT05553041",
    "official_title": "Evaluation of 18F-Fluciclovine PET-MRI to Differentiate Tumor Progression From Post-treatment Changes in Pediatric High-grade Glioma (HGG)",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 1 Year\nMust have maximum age of 21 Years",
    "exclusion_criteria": "* 1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.\n* 2. Pregnant or breastfeeding participants.\n* 3. Participant who would require sedation or anesthesia for imaging beyond standard of care (SOC).\n* 4. Participants who weigh less than 8 kg.\n* 5. Participants who cannot avoid contact with a pregnant woman or infant for at least 12 hours following injection.\n* 6. Participants with a history of abnormal kidney function or creatinine &gt;= CTCAE v5.0 grade 2 at time of study registration.\n\n  7. Participants with primary tumors of the spinal cord.",
    "miscellaneous_criteria": "Inclusion Criteria\n\n* 1. Histopathology-proven HGG (WHO grade III-IV) or DMG (WHO grade IV) or, in the case of DMG of the pons, imaging that is characteristic of Diffuse intrinsic pontine gliomas (DIPG) (diffusely infiltrating &gt;=2/3 of the pons).\n* 2. Measurable disease, measuring at least 1x1 cm.\n* 3. Life expectancy of greater than 8 weeks.\n* 4. Age &gt; 1 years but &lt; 21 years of age at enrollment.\n\nFor those without planned surgery:\n\n* 1. Participants with clinical and/or radiographic suspicion of True progression (TP) or Pseudoprogression (PsP) during radiation but yet to have the initial post-radiation MRI scan.\n\nor\n\n* 2. Participants with suspicion for TP or PsP on first post-radiation MRI\n\nFor those with planned surgery:\n\n* 1. Clinical or radiographic suspicion of tumor progression with plan to undergo surgery or biopsy."
}